Environmentally responsive targeted micelle for treating drug-resistant bacterial infection, preparation method and application

By designing environmentally responsive targeted micelles, using pH environmentally responsive materials and antimicrobial peptide modifications, the solubility and stability of azithromycin and curcumin in bacterial infection sites were solved, and efficient treatment of drug-resistant bacteria was achieved.

CN117815178BActive Publication Date: 2024-11-26LIAONING UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410014731.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-04
Publication Date
2024-11-26
Estimated Expiration
2044-01-04

AI Technical Summary

Technical Problem

The prior art is difficult to deliver the therapeutic drugs azithromycin and curcumin through polymer micelles, improve the solubility and stability of the drug, and achieve specific treatment of bacterial infection sites, especially for drug-resistant bacteria.

Method used

Design an environmentally responsive targeted micelle, using pH environmentally responsive materials such as mPEG114-PDPA10 and vitamin E polyethylene glycol succinate, containing azithromycin and curcumin, and modify the antimicrobial peptide MagII in the micelle shell, using Environmental responsiveness and targeting improve drug localization and release efficiency.

Benefits of technology

It significantly improves the inhibitory effect of drugs on drug-resistant bacteria, increases drug intake of bacteria, extends the time of drug action in the body, reduces the dosage of drugs, and improves the solubility and stability of drugs, achieving infection with drug-resistant bacteria effective treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117815178B_ABST
    Figure CN117815178B_ABST
Patent Text Reader

Abstract

The present invention discloses an environmentally responsive targeted micelle, a preparation method and an application for treating drug-resistant bacterial infection, and belongs to the field of new drug delivery preparations of traditional Chinese medicine. The environmentally responsive targeted micelle includes a base material and a micelle composed of a therapeutic drug encapsulated by the base material, and a targeting molecule targeting the micelle; wherein the base material includes a pH environmentally responsive material, vitamin E polyethylene glycol succinate and distearoylphosphatidylethanolamine-polyethylene glycol 2000, the therapeutic drug includes azithromycin and curcumin, and the targeting molecule includes distearoylphosphatidylethanolamine-polyethylene glycol 2000-MagII. The environmentally responsive targeted micelle of the present invention improves the solubility of fat-soluble drugs, has good targeting, can significantly increase the drug uptake of bacteria, inhibit bacterial activity, inhibit biofilm formation, thereby improving drug activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of novel drug delivery preparations of traditional Chinese medicine, and in particular to an environmentally responsive targeted micelle for treating drug-resistant bacterial infection, a preparation method and application thereof. Background Art

[0002] Bacterial infection is an acute infection caused by pathogenic bacteria or conditional pathogens invading the blood circulation and producing toxins and other metabolites. It is reported that bacterial infection is the second leading cause of death in the world after heart disease, accounting for one-eighth of all deaths in 2019, of which Staphylococcus aureus and Streptococcus pneumoniae are the most deadly bacteria. Since their invention in the last century, antibiotics have played an important role in the prevention and treatment of bacterial infections. However, with the widespread use of such drugs in medical, animal husbandry and other fields, bacteria have evolved drug-resistant genes after repeated exposure to antibiotic drugs. Drug-resistant bacterial infections can cause local infections such as purulent inflammation of the skin, mucous membranes, tissues and organs, pneumonia, and eventually induce systemic infections such as sepsis. It has become an increasingly serious public health problem worldwide, and there is an urgent need to develop new antibacterial agents or new effective drug delivery systems.

[0003] Combination therapy of antibiotics is a common clinical treatment for bacterial resistance. Azithromycin is a semi-synthetic 15-membered macrolide antibiotic with a wide range of clinical applications. It has the advantages of a broad antibacterial spectrum, low gastrointestinal irritation, and rapid oral absorption. Studies have shown that azithromycin combined with antibiotics can effectively inhibit bacterial growth and the early formation of biofilms in vitro. However, in order to avoid the generation of superbugs caused by excessive use of antibiotics, the inventors considered choosing a safe drug instead of combining antibiotics with azithromycin to improve the effectiveness of treating infections.

[0004] As a natural medicine, Chinese medicine has a wide range of sources, high safety, and low toxicity and side effects. Many Chinese herbal medicines have been found to have antibacterial and bactericidal effects. It has also been reported that the combination of Chinese medicine monomers and antibiotics can effectively inhibit the growth of drug-resistant bacteria. Curcumin is one of the world's largest natural food pigments, which is isolated from the rhizome of turmeric. It has a wide range of pharmacological activities such as anti-inflammatory, anti-infective, anti-viral, antioxidant, and anti-tumor, with low toxicity and few adverse reactions. It can be used as an ideal drug for combination with antibiotics.

[0005] However, curcumin has poor solubility in water, low bioavailability for oral absorption, and poor stability. Azithromycin also has the disadvantages of poor water solubility and strong side effects. Polymer micelles have attracted more and more attention in many emerging drug delivery systems because they can significantly improve the solubility of hydrophobic drugs. However, there are currently no reports on the delivery of therapeutic drugs azithromycin and curcumin by polymer micelles, and how to deliver therapeutic drugs azithromycin and curcumin by polymer micelles, reduce the dosage, improve the solubility and stability of fat-soluble drugs, prolong the cycle of drugs in the body, and achieve specific treatment of bacterial infection sites is an urgent problem to be solved. Summary of the invention

[0006] The purpose of the present invention is to provide an environmentally responsive targeted micelle for treating drug-resistant bacterial infections, a preparation method and an application thereof, so as to solve the problems existing in the above-mentioned prior art. The environmentally responsive targeted micelle can locate and target the drug to the bacterial infection site according to the pathological microenvironment of the bacterial infection site, and can enhance the therapeutic effect of the drug on drug-resistant bacteria through the synergistic enhancement of the antibiotic azithromycin and the traditional Chinese medicine curcumin, thereby achieving better therapeutic effect.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The present invention provides an environmentally responsive targeted micelle for treating drug-resistant bacterial infection. The environmentally responsive targeted micelle comprises a micelle composed of a basic material and a therapeutic drug encapsulated by the basic material, and a targeting molecule targeting the micelle; wherein the basic material comprises a pH environmentally responsive material, vitamin E polyethylene glycol succinate and distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the therapeutic drug comprises azithromycin and curcumin, and the targeting molecule comprises distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII.

[0009] Preferably, the pH environment responsive material comprises mPEG114-PDPA10.

[0010] Preferably, the mass ratio of the pH environment responsive material, the vitamin E polyethylene glycol succinate, the distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the azithromycin, the curcumin and the distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII is (60-80):(10-25):(1-3):1:(1-3):(1-3).

[0011] Preferably, the mass ratio of the pH environment responsive material, the vitamin E polyethylene glycol succinate, the distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the azithromycin, the curcumin and the distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII is 80:20:2:1:2:2.

[0012] The present invention also provides a method for preparing the environmentally responsive targeted micelles for treating drug-resistant bacterial infection, comprising the following steps:

[0013] The pH environment-responsive material, the vitamin E polyethylene glycol succinate, the distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the azithromycin, the curcumin and the distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII are weighed according to the required amounts, completely dissolved with methanol, and the methanol is evaporated to form a transparent film; after cooling, it is placed in a 40°C water bath for preheating for 1 min, and then PBS buffer is added and shaken at 40°C for 20 min to obtain a solution, and the solution is absorbed and filtered through a 0.22μm microporous filter membrane to obtain environmentally responsive targeted micelles for treating drug-resistant bacterial infections.

[0014] Preferably, the mass volume ratio of the pH environment responsive material to the methanol is (60-80) mg: (3-5) mL;

[0015] The mass volume ratio of the pH environment responsive material to the PBS buffer is (60-80) mg: (3-5) mL.

[0016] The present invention also provides the use of the environmentally responsive targeted micelle in the preparation of a drug for treating drug-resistant bacterial infection.

[0017] Preferably, the drug for treating drug-resistant bacterial infection includes drugs for treating drug-resistant Staphylococcus aureus infection and drug-resistant Streptococcus pneumoniae infection.

[0018] The present invention discloses the following technical effects:

[0019] In order to avoid bacterial super-resistance caused by excessive use of antibiotics, the present invention constructs an environmentally responsive targeted micelle for treating drug-resistant bacterial infection. The environmentally responsive targeted micelle is an azithromycin and curcumin micelle composed of environmentally responsive materials mPEG114-PDPA10 and TPGS1000, and the antimicrobial peptide MagII is modified on the micelle shell. The therapeutic effect of the environmentally responsive targeted micelle on different infection sites is verified by experiments. The results show that the combined use of azithromycin and curcumin avoids further drug resistance of resistant bacteria caused by dual antibiotics; and encapsulating azithromycin and curcumin in the hydrophobic core of the micelle improves the solubility of fat-soluble drugs. The micelle is constructed using the environmentally responsive material mPEG114-PDPA10, and the hydrophilic shell of the micelle is modified with the targeting molecule DSPE-PEG2000-MagII, so that the drug is released in a slightly acidic environment of bacterial infection and concentrated at the infection site. The environmentally responsive targeted micelle has good targeting, significantly increases bacterial drug uptake, inhibits bacterial activity, and further inhibits biofilm formation, thereby improving drug activity. Therefore, the environmentally responsive targeted micelle prepared by the present invention can achieve precise drug delivery, reduce drug dosage, improve the solubility and stability of fat-soluble drugs, and prolong the drug cycle in the body, which is of great significance for the treatment of drug-resistant bacterial infections. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1 Characterization of the environmentally responsive targeted micelle MagII-AZI / Cur-Ms prepared by the present invention; A is a transmission electron microscopy image of the micelle; B is a micelle size distribution image; C is a Zeta potential image; D is a PDI result image; E is a critical micelle concentration determination image; F is an AZI in vitro release image; G is a Cur in vitro release image; H is a micelle stability result;

[0022] Figure 2 Figure 2 shows the bacterial uptake graph (A) and the quantitative analysis graph of bacterial uptake (B);

[0023] Figure 3 The antibacterial effect of the environmentally responsive targeted micelle MagII-AZI / Cur-Ms prepared by the present invention; A is a time-killing curve; B is the inhibition zone result; C is the inhibition zone quantitative analysis diagram; D is a crystal violet staining diagram; E is a crystal violet staining quantitative analysis diagram; F is a biofilm live and dead bacteria staining diagram;

[0024] Figure 4 Live imaging of mice infected with skin and muscle; A is a live imaging of mice infected with skin; B is a live imaging of mice infected with muscle;

[0025] Figure 5 The results of the evaluation of the efficacy of different micelles against bacterial infection; A is a representative picture of the skin infection mouse model; B is a representative picture of the muscle infection mouse model; C is HE staining of mouse skin after treatment; D is HE staining of mouse muscle after treatment;

[0026] Figure 6 A is the expression of serum inflammatory factors in mice with skin and muscle infection; AC is the expression of serum inflammatory factors TNF-α, IL-1β and IL-6 in mice with skin infection; DF is the expression of serum inflammatory factors TNF-α, IL-1β and IL-6 in mice with muscle infection. DETAILED DESCRIPTION

[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0028] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0029] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0030] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0031] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0032] The main experimental instruments and materials involved in the following examples are:

[0033] (1) Experimental instruments

[0034] XS105 1 / 100,000 balance (Mettler Toledo); SG3300H ultrasonic cleaner (Shanghai Guante Ultrasonic Instrument Co., Ltd.); RE52CS rotary evaporator (Shanghai Yarong Biochemical Instrument Factory); DZKW-S-4 electric constant temperature water bath (Shanghai Medical Equipment Company Medical Equipment Factory No. 5); dextran gel column (Sephadex G-50, Shanghai Hualan Chemical Technology Co., Ltd.); 500A nanoparticle size and Zeta potential analyzer (Anton Paar, Austria); JEM-2000EX transmission electron microscope (Japan Electronics Co., Ltd.); HBS-1096A microplate reader (Nanjing Detie Experimental Equipment Co., Ltd.); 1100 liquid chromatograph (UV detector, Dalian Yilite); C18 chromatographic column (250mm×4.6mm, 5μm, Shanghai Yuexu); SW-CJ-1D single-person clean bench (Shanghai Sujing Industrial Co., Ltd.); gas-jacketed carbon dioxide cell culture incubator (ThermoFlesher Scientific (Asheville) LLC, USA); Ti-S fluorescence inverted microscope (Nikon, Japan); confocal microscope (Leica, Germany); multispectral in vivo imaging system (Carestream Health, Inc., USA); RM2235 paraffin slicer (Leica, Germany).

[0035] (2) Experimental Materials

[0036] Azithromycin (AZI) (Dalian Meilun Biotechnology Co., Ltd., purity>96%); Curcumin (Cur) (Dalian Meilun Biotechnology Co., Ltd., purity>97%); MagII (TagerMol China, Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Asn-Se r); Vitamin E polyethylene glycol succinate (TPGS) (Dalian Meilun Biotechnology Co., Ltd.); mPEG114-PDPA10, distearoyl phosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000), distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII (DSPE-PEG2000-MagII) (Xi'an Ruixi Biotechnology Co., Ltd.); IL-6, IL-1β, TNF-α kits (Beijing Solaibao Technology Co., Ltd.); the rest of the reagents were of analytical grade, and water was purified water.

[0037] Example 1

[0038] 1. Preparation of micelles

[0039] 1.1 Preparation of environmentally responsive bacteria-targeted micelles

[0040] The micelles were prepared by thin film hydration method. The specific steps are as follows:

[0041] Accurately weigh mPEG 114 -PDPA 10 80mg, TPGS 1000 20mg, DSPE-PEG 2000 2mg, DSPE-PEG 2000 -MagII 2mg, AZI 1mg and Cur 2mg were placed in a 50mL round-bottom flask, 5mL of methanol was added and ultrasonically vibrated for 10 minutes to completely dissolve them, and then placed in a 40℃ water bath and decompressed and rotary evaporated to remove the methanol. At this time, a layer of transparent film was tightly attached to the inner wall of the flask. After the round-bottom flask was cooled, the bottom of the flask was placed in a 40℃ water bath and preheated for 1 minute, and then 5mL of PBS buffer was added and shaken at 40℃ for 20 minutes. Finally, a 5mL medical syringe was used to absorb and squeeze through a 0.22μm microporous filter membrane twice to obtain the environmentally responsive targeted micelles MagII-AZI / Cur-Ms for the treatment of drug-resistant bacterial infections. During the preparation process, DSPE-PEG was not added 2000 -MagII, AZI and Cur to obtain Blank-Ms; DSPE-PEG is not added 2000 - AZI-Ms is obtained by combining MagII and Cur; DSPE-PEG is not added2000 -MagII gives AZI / Cur-Ms.

[0042] 1.2 Preparation of Cou-Ms

[0043] Cou-Ms was prepared by the same method as above, where AZI and Cur were replaced by coumarin (Cou).

[0044] 1.3 Preparation of DiR-Ms

[0045] DiR-Ms was prepared by the same method as above, where AZI and Cur were replaced by the fluorescent reagent DiR.

[0046] 2. Characterization of micelles

[0047] 2.1 Micellar morphology observation

[0048] Take appropriate amount of each of the above micelle solutions and dilute them 50 times with PBS. Take appropriate amount of the diluted liposome solution and drop it onto the copper grid for electron microscopy, stain it with 2% phosphotungstic acid solution, dry it at room temperature, and observe its morphology on a transmission electron microscope (the acceleration voltage of the transmission electron microscope is 120 kV).

[0049] 2.2 Particle size and Zeta potential determination

[0050] Take appropriate amount of each micelle solution and use laser particle size analyzer to measure the particle size and Zeta potential of liposomes. The particle size is set to be measured 500 times each time, and the Zeta potential is set to be measured 1000 times each time, and the operation is repeated 3 times.

[0051] 2.3 Determination of critical micelle concentration

[0052] Accurately weigh 40.4 mg of pyrene and place it in a 10 mL volumetric flask, dilute to volume with acetone, and then dilute 100 times to obtain 2 × 10 - 4 mol / L stock solution. Blank-Ms was prepared to 1×10 -6 mg / mL, 2.5×10 -6 mg / mL, 5×10 -6 mg / mL, 1×10 - 5 mg / mL, 2.5×10 -5 mg / mL, 5×10 -5 mg / mL, 1×10 -4 mg / mL, 2.5×10 -4 mg / mL, 5×10 -4 mg / mL, 1×10 -3 mg / mL, 2.5×10 -3 mg / mL, 5×10-3 mg / mL solution.

[0053] Add 80 μL of pyrene stock solution to the test tube and dry it naturally overnight in the dark. Use a pipette to draw 8 mL of the above solution and add it to the test tube so that the final concentration of pyrene is 2×10 -6 mol / L. Seal the test tube and shake gently to mix evenly. Place in a dark place overnight. Filter the liquid in the test tube using a 0.22μm microporous filter membrane, set 340nm as the emission wavelength, and record the excitation fluorescence spectrum from 300-360nm.

[0054] 2.4 In vitro release rate determination

[0055] A PBS solution containing 10% FBS was used as the release medium to simulate the in vivo release behavior. Take two dialysis bags cut to appropriate sizes, add 1 mL of equal volume of MagII-AZI / Cur-Ms solution to each of them, and seal the bags after leaving air approximately equal to the volume of the liquid in the bags. The dialysis bags were floated in 100 mL of release medium at pH 7.4 and pH 6.5, respectively, and magnetic stirring was used to promote release. 0.5 mL of release medium was drawn from the beaker as a sample at 6 h, 12 h, 24 h, 48 h, and 72 h, and an equal volume of fresh medium was added. The HPLC spectra of AZI and Cur at different sampling time points were tested respectively. The in vitro release rate was calculated according to the following formula:

[0056] In vitro release rate (%) = drug content in release medium / dose × 100%

[0057] 2.5 Encapsulation efficiency determination method

[0058] Place 2.0g Sephadex G-50 in PBS solution, swell at room temperature for 12h, and then load the column (10cm×1.5cm) for later use. Take 1mL MagII-AZI / Cur-Ms and slowly drip it onto the top of the dextran gel column, add PBS for elution, perform chromatographic separation, collect the opalescent part of the liquid after passing through the column, and dilute to 1mL with PBS and mix well. Accurately pipette 500μL into an EP tube, add an equal volume of methanol for ultrasonic demulsification. Take the micelles before and after the column and dilute to volume, add methanol solution at a volume ratio of 1:4, mix well, and ultrasonically demulsify. After demulsification, pass the solution through a 0.45μm microporous filter membrane to filter out the membrane material and drugs that are not encapsulated, and take the filtrate for later use. The chromatographic system uses Elite 1100 high performance liquid chromatography, and the chromatographic column is C 18(4.6mm×250mm, 5μm). AZI mobile phase: 0.05mol / L potassium dihydrogen phosphate (pH8.2): acetonitrile = 45:55, liquid chromatography conditions: detection wavelength 210nm, flow rate 1mL / min, injection volume 20μL each time, column temperature 30℃. Cur mobile phase: acetonitrile: 0.05% phosphoric acid water = 67:33, liquid chromatography conditions: detection wavelength 430nm, flow rate 1mL / min, injection volume 20μL each time, column temperature 30℃. The encapsulation efficiency (EE%) of the drug in the liposome was calculated according to the following formula:

[0059] EE (%) = drug peak area after column / drug peak area before column × 100.

[0060] 2.6 Evaluation of micelle stability

[0061] Three batches of MagII-AZI / Cur-Ms were prepared in vials and sealed. The sealed liposomes were stored in a 4°C refrigerator and at room temperature (25°C), and taken out at 5d, 10d, 15d and 20d to investigate the micelle encapsulation efficiency.

[0062] 3. In vitro targeting evaluation of MagII-AZI / Cur-Ms

[0063] 3.1 Bacterial culture

[0064] Methicillin-resistant Staphylococcus aureus (MRSA) was inoculated into LB solid medium, cultured in an incubator at 37°C for 24 hours, and a single colony was picked and placed in liquid medium. After culture at 37°C for 12 hours, the colony was divided into aliquots at a ratio of bacterial liquid: glycerol = 4:1 (V / V), and placed at -80°C for use. In the experiment, the colony was thawed at room temperature and activated in liquid medium for 12 hours before use.

[0065] 3.2 Minimum inhibitory concentration

[0066] The in vitro minimum inhibitory concentration of each group of micelles against MRSA was determined by the microbroth dilution method. The culture solution was taken and the concentration was adjusted to 1×10 6 CFU / mL, added to a sterile 96-well culture plate. The dosage concentrations were 20μg / mL, 15μg / mL, 10μg / mL, 8μg / mL, 6μg / mL, 4μg / mL, 2μg / mL, 1μg / mL, and 0.5μg / mL. The mixed 96-well culture plate was placed in a 37°C incubator for 24 hours. The lowest drug concentration without bacterial growth was observed with the naked eye, which was the MIC of MagII-AZI / Cur-Ms against MRSA. Each group of the test was repeated six times.

[0067] 3.3 Time-killing curve

[0068] Take the culture solution and adjust the concentration to 1×10 6 CFU / mL, added to a sterile 96-well culture plate, the drug concentration is 1×MIC. The mixed 96-well culture plate was placed in a 37°C incubator for 24 hours, and the OD of the 96-well plate was measured every 1 hour using a multifunctional microplate reader. 600 The OD value of 24h was repeated four times. 600 Draw the curve with the value.

[0069] 3.4 Inhibition zone

[0070] MRSA was inoculated on solid culture medium and cultured for 24 h to prepare a culture medium containing about 1×10 6 CFU / mL bacterial suspension, use the bacterial suspension to make bacteria-containing plates. Paste blank drug-sensitive paper sheets into the bacteria-containing plates, put 4 sheets in each plate, take 25μL of each sample and drop it on the paper sheets. After culturing for 24 hours, measure the diameter of the inhibition zone vertically.

[0071] 3.5 Effects on biofilm

[0072] Crystal violet staining was used to detect the activity of micelles in preventing bacterial biofilm. 6 CFU / mL), added to a 96-well cell culture plate (200 μL / well), 1 / 4MIC was used to determine the antimicrobial biofilm activity, and the 96-well cell culture plate was incubated at 37°C for 24 hours. Each dosing group was tested in three parallel replicates. Remove the floating bacteria in the 96-well cell culture plate, wash it 2-3 times with PBS solution, be careful not to contact the biofilm, and then stain the biofilm in the 96-well cell culture plate with crystal violet. Wash it 2-3 times with PBS solution, dry it, dissolve it with 33% acetic acid, detect it using a multifunctional enzyme meter, and read the OD value at 595nm.

[0073] 3.6 Biofilm live / dead bacterial staining

[0074] To observe the therapeutic effects of different treatment groups on bacterial biofilms, the treated biofilms were stained with dyes SYTO-9 and PI. 6CFU / mL), added it to a 96-well cell culture plate (200μL / well), and incubated the 96-well cell culture plate at 37°C for 24h. The biofilm was treated with different groups of micelle solutions at 37°C for 3 hours, and 1 / 4MIC was used to determine the antimicrobial biofilm activity. The supernatant was discarded and washed three times with PBS buffer. Subsequently, PBS buffer containing SYTO-9 (2μM) and PI (1μM) was added in the dark and stained at room temperature for 15 minutes. After staining, the excess dye solution was washed away, and the two fluorescent dyes in the biofilm were observed by laser confocal microscopy to evaluate the anti-MRSA biofilm effect of the micelles.

[0075] 4. Bacterial uptake experiment

[0076] Laser confocal microscopy was used to observe the uptake of different micelles in bacteria. 6 CFU / mL density was incubated with Cou-Ms, and after 2 hours, the medium was discarded by centrifugation, and the excess liposomes that were not taken up were washed with PBS. The cells were resuspended in pre-cooled PBS, fixed with 4% paraformaldehyde for 15 minutes, and PDAI stained the cell nucleus for 10 minutes. The distribution of fluorescence in the cells was observed using a laser confocal microscope.

[0077] 5. In vivo targeting evaluation

[0078] 5.1 Establishment of skin infection mouse model

[0079] A mouse model of skin infection was established by subcutaneous injection. A single MRSA colony was picked and inoculated into LB broth, cultured at 180 r / min and 37°C for 22 h. After washing with PBS, the cells were resuspended to a final concentration of 5×10 8 CFU / mL, for later use. Observe the back skin of the experimental mice 24 hours before modeling, select mice with good skin condition for the experiment, and use a razor and depilatory cream to treat the back hair of the experimental mice 24 hours before modeling to expose the back skin, and then group and adapt. The blank group mice pinched the skin and injected 0.1mL of normal saline subcutaneously for control. The infected group was injected with 0.1mL of bacterial solution subcutaneously and the skin bulge was observed. The back skin of the infected group was closely observed within 24 hours, and the model was successful when purulent lesions appeared at the depilated area.

[0080] 5.2 Establishment of skin infection mouse model

[0081] A mouse model of muscle infection was established by intramuscular injection. A single MRSA colony was selected and inoculated into LB broth, cultured at 180 r / min and 37°C for 22 h. After washing with PBS, the cells were resuspended to a final concentration of 5×10 8CFU / mL, for later use. 24h before modeling, the legs of the experimental mice were treated with a razor and depilatory cream to expose the skin, and then grouped and adapted. The blank group mice were injected intramuscularly with 0.1mL of normal saline for control, and the infected group was injected intramuscularly with 0.1mL of bacterial solution and observed. The skin of the legs of the infected group was closely observed within 24h, and the model was successful when red and swollen lesions appeared in the muscles.

[0082] 5.3 In vivo imaging of small animals

[0083] In vivo imaging experiments were used to investigate the in vivo targeting of different preparations. The drug was replaced with the fluorescent reagent DiR. The mice were divided into the following groups: ① saline (Control); ② free DiR (Free DiR); ③ DiR micelles (DiR-Ms); ④ MagII-modified DiR liposomes (MagII-DiR-Ms). The DiR dose in each dosing group was ensured to be the same, all at 2μg / mouse. The mice were anesthetized with isoflurane, and the fluorescence signals in each group of mice were monitored using an in vivo imaging system. Fluorescence imaging was performed on the mice at different time points (2h, 4h, 6h, 8h, 10h, 24h, 48h, 72h and 96h) to observe the intensity of the fluorescence signal in vivo.

[0084] 6. Pharmacodynamic evaluation of MagII-AZI / Cur-Ms

[0085] 6.1 Animal grouping

[0086] The tumor-bearing mice were divided into: ① blank control group; ② model group; ③ free AZI and Cur (AZI / Cur); ④ AZI and Cur micelles (AZI / Cur-Ms); ⑤ MagII-modified AZI and Cur micelles (MagII-AZI / Cur-Ms). The different preparations were injected into the tail vein once every 2 days for 3 times.

[0087] 6.2 HE staining

[0088] Mice were anesthetized with 7% chloral hydrate, and the skin or muscle tissue of the infected area was quickly peeled off. The infected area was fixed with 4% paraformaldehyde for 24 hours, embedded in paraffin wax, and the coronal sections were 5μm thick. Dewaxed in xylene twice, 5min / time. Hydrated with 100%, 95%, 85%, and 75% ethanol respectively, and washed with tap water for 2min. Stained with hematoxylin solution for 15min and washed with tap water. Differentiated with acidic differentiation solution for 30s and washed with tap water for 20min. Stained with eosin solution for 1min and washed with tap water for 2min. Dehydrated with 75%, 85%, 95%, and 100% ethanol in turn, transparentized with xylene twice, sealed with neutral gum, and observed the pathological changes of cells under an inverted microscope.

[0089] 6.3 Detection of inflammatory factor expression levels

[0090] ELISA kits were used to detect the expression levels of inflammatory factors IL-6, IL-1β, and TNF-α in the serum of mice after treatment. Blood was collected from the eye sockets of mice, and after standing for 30 minutes, it was centrifuged at 4°C and 10,000 rpm for 10 minutes, and the supernatant was taken and tested using the corresponding kits.

[0091] 7. Statistical analysis

[0092] Graphpad Prism 9.0 software was used for statistical analysis. All experimental data were expressed as Mean ± SD. One-way analysis of variance was used for comparison among multiple groups, and LSD-t test was used for further pairwise comparison. P < 0.05 indicated that the difference was statistically significant.

[0093] 8. Results and Analysis

[0094] 8.1 Characterization of micelles

[0095] like Figure 1 As shown in Figure A, it is a transmission electron microscopy photograph of the MagII-modified environmentally responsive micelles encapsulating AZI and Cur. It can be seen that the prepared MagII-AZI / Cur-Ms is spherical or quasi-spherical, with a smooth and round surface and uniform size. Figure 1 As shown in BD, the particle size and Zeta potential of the micelles were measured using a nanoparticle size and Zeta potential analyzer. The results showed that the surface Zeta potential of MagII-AZI / Cur-Ms was -(1.27±0.15) mV. Under pH 7.4 conditions, the particle size of MagII-AZI / Cur-Ms was (36.19±1.46) nm, and the particle size distribution conformed to the normal distribution characteristics, with a narrow polydispersity coefficient (PDI, 0.224±0.002). However, in a slightly acidic environment that simulates a bacterial infection environment, the particle size of MagII-AZI / Cur-Ms was (127.38±2.02) nm, which was significantly increased compared to the particle size under pH 7.4 conditions. Figure 1 As shown in E, it shows the I 373 / I 384 The fluorescence ratio is plotted as a function of the concentration of the mixed copolymer, and the calculated CMC value is 0.0178 mg / mL, indicating that the micelle has good stability and can maintain its structural integrity under dilution conditions. Figure 1 H in the figure shows the results of the liposome stability evaluation. The results show that there is a slight leakage of AZI and Cur in the micelles within 20 days at 37°C and 4°C. The release rate of each micelle in the release medium simulating the blood environment in vivo is about 30% at 72 hours, but it has a higher release rate in a slightly acidic environment, indicating that the micelles have good responsiveness (see Figure 1 F and G).

[0096] 8.2 Evaluation of micelle targeting in vitro

[0097] The results of cellular uptake are shown in Figure 2 Fluorescent coumarin was selected as a fluorescent probe to investigate targeting. The intracellular drug fluorescence intensity was observed using a confocal microscope. Figure 2 As shown in A, it is a representative image of bacteria taking up different liposomes. Figure 2 B in the figure is the result of quantitative analysis, which shows that the modification of MagII can significantly enhance the bacterial uptake of Cou.

[0098] 8.3 Evaluation of the antibacterial effect of micelles in vitro

[0099] In vitro antibacterial effect of MagII-AZI / Cur-Ms Figure 3 The results of minimum inhibitory concentration (see Table 1) show that after AZI and Cur were co-encapsulated in micelles, the MIC was reduced, and the MIC was further reduced after the micelles were modified with MagII. Figure 3 AC) further showed that MagII-AZI / Cur-Ms could effectively inhibit the growth of MRSA. Figure 3 As shown in Figures DE, the number of surviving bacterial colonies in the biofilm decreased significantly after treatment with MagII-AZI / Cur-Ms. The live / dead bacterial staining results showed that MagII-AZI / Cur-Ms still had a significant inhibitory effect on mature biofilms (see Figure 3 Middle F).

[0100] Table 1 Minimum inhibitory concentration results

[0101]

[0102] 8.4 In vivo targeting evaluation

[0103] The in vivo fluorescence imaging system was used to observe the distribution of fluorescence signals in mice at different time points. The results of in vivo imaging of skin infection and muscle infection model mice are shown in Figure 2. Figure 4 A and B. The results showed that a weak fluorescence signal could be observed at the skin infection site of mice in the Free DiR group during 2-24 hours, and no fluorescence signal was observed after 24 hours, and no fluorescence signal was observed at the muscle infection site. Obvious fluorescence signals were observed at the infection site of mice in different micelle groups during 2-96 hours, and the MagII-DiR-Ms group had the strongest fluorescence signal at the infection site at each time point. The results showed that the modification of MagII made the micelles have better targeting.

[0104] 5. Evaluation of the in vivo efficacy of micelles

[0105] The results of the evaluation of the efficacy of different micelles against bacterial infection are shown in Figure 5 . Figure 5 A and B are representative images of the animal models of skin infection and muscle infection after treatment. The results show that after treatment, the abscesses at the subcutaneous infection site disappeared and scabs formed; the redness and swelling at the muscle infection site were reduced, and the leg activity of the mice was restored (see Figure 5 In the CD model, the expression of inflammatory factors in both models was also decreased (see Figure 6 Medium AF).

[0106] PDPA is a pH-responsive polymer. When the pH value is lower than pKa, the N of the amino group undergoes hydrophobic or hydrophilic conversion, and can be used as a carrier to deliver drugs to the acidic bacterial infection microenvironment. TPGS is a nonionic surfactant formed by the esterification reaction of vitamin E succinic acid and polyethylene glycol 1000. It has a tocopherol structure, which can destroy the bacterial membrane structure, increase the permeability of the membrane structure, and inhibit the efflux pump in drug-resistant bacteria. The present invention modifies the antimicrobial peptide MagII to the micelle shell by designing a micelle containing azithromycin and curcumin composed of PDPA and TPGS1000. MagII targets the micelle shell with environmental responsiveness and antibacterial properties to the bacterial infection site, and positions and releases the therapeutic drugs azithromycin and curcumin to reduce the dosage, improve the solubility and stability of fat-soluble drugs, and prolong the cycle of the drug in the body. The data of the above examples also verify that MagII-AZI / Cur-Ms can significantly promote bacterial uptake, accurately deliver to the bacterial infection site, and effectively inhibit bacterial infection.

[0107] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. An environmentally responsive targeted micelle for the treatment of drug-resistant bacterial infections. It is characterized in that The environmentally responsive targeted micelles include micelles composed of a base material and a therapeutic drug encapsulated by the base material, and a targeting molecule of the targeted micelles; wherein the base material includes a pH environmentally responsive material, vitamin E polyethylene glycol succinate and distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the therapeutic drugs are azithromycin and curcumin, and the targeting molecule includes distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII; The mass ratio of the pH environment responsive material, the vitamin E polyethylene glycol succinate, the distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the azithromycin, the curcumin and the distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII is 80:20:2:1:2:2; The pH environment responsive material is mPEG114-PDPA10.

2. A method for preparing an environmentally responsive targeted micelle for treating drug-resistant bacterial infection as claimed in claim 1, It is characterized in that The following steps are involved: The pH environment-responsive material, the vitamin E polyethylene glycol succinate, the distearoyl phosphatidylethanolamine-polyethylene glycol 2000, the azithromycin, the curcumin and the distearoyl phosphatidylethanolamine-polyethylene glycol 2000-MagII are weighed according to the required amounts, completely dissolved with methanol, and the methanol is evaporated to form a transparent film; after cooling, it is placed in a 40°C water bath for preheating for 1 min, and then PBS buffer is added and shaken at 40°C for 20 min to obtain a solution, and the solution is absorbed and filtered through a 0.22 μm microporous filter membrane to obtain environmentally responsive targeted micelles for treating drug-resistant bacterial infections.

3. The preparation method according to claim 2, It is characterized in that The mass volume ratio of the pH environment responsive material to the methanol is (60-80) mg: (3-5) mL; The mass volume ratio of the pH environment responsive material to the PBS buffer solution is (60-80) mg: (3-5) mL.

4. Use of the environmentally responsive targeted micelle according to claim 1 in the preparation of a drug for treating drug-resistant bacterial infection, It is characterized in that The drug-resistant bacteria is methicillin-resistant Staphylococcus aureus.